<DOC>
	<DOCNO>NCT00260689</DOCNO>
	<brief_summary>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic bone marrow transplantation offer opportunity cure 70 % patient , patient suitable candidate hematopoietic stem cell transplantation ( HSCT ) due advanced age lack histocompatible donor . For patient , comparable long term survival attainable immunosuppressive treatment anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) . However , patient treat horse ATG ( h-ATG ) /CsA , one quarter one third respond , 50 % responder relapse . Auto-reactive T cell may resistant effect ATG/CsA ( non-responders ) , others residual auto-reactive T cell expand post-treatment , lead hematopoietic stem cell destruction recurrent pancytopenia ( relapse ) . As long term survival correlate response rate robustness hematopoietic recovery , novel immunosuppressive regimen achieve hematologic response decrease relapse rate need . This trial compare effectiveness three immunosuppressive regimen first line therapy patient SAA early hematologic response primary endpoint , well assess role extend CsA treatment h-ATG reduce number late event relapse clonal evolution . Randomization employ obtain equal distribution subject arm ; comparison early hematologic response make among rate observe among three concurrent arm ( rabbit-ATG [ r-ATG ] versus standard h-ATG ; alemtuzumab vs standard h-ATG ) . For long course CSA , comparison primary end point well establish historic relapse rate 38 % 2-3 year cumulative rate clonal evolution 15 % . In original design subject randomize one three different regimen : h-ATG + 6 month CsA follow 18 month CsA taper ; r-ATG + 6 month CsA ; alemtuzumab ( Campath ) . Subjects fail respond r-ATG cross alemtuzumab ( Campath ) , subject fail alemtuzumab ( Campath ) cross r-ATG . Subjects fail respond h-ATG + CsA taper go study evaluate eligibility second course immunosuppression companion protocol 03-H-0249 , similarly randomizes subject r-ATG alemtuzumab ( Campath ) salvage therapy . The Campath arm close new accrual lack efficacy 4/10/2008 . New accrual randomize h-ATG + 6 month CsA follow 18 month CsA taper r-ATG + 6 month CsA . Subjects fail respond r-ATG continue cross alemtuzumab ( Campath ) . Subjects fail respond h-ATG + CsA taper go study evaluate eligibility second course immunosuppression companion protocol 03-H-0249 , similarly randomizes subject r-ATG alemtuzumab ( Campath ) salvage therapy . The primary endpoint hematologic respnse , define longer meet criterion SAA , 6 month . Secondary endpoint relapse , robustness hematologic recovery 6 month , response 3 12 month , survival , clonal evolution PNH , myelodysplasia acute leukemia . Long-course CSA assess separately efficacy reduce late event relapse evolution comparison historical control data .</brief_summary>
	<brief_title>Three Immunosuppressive Treatment Regimens Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic bone marrow transplantation offer opportunity cure 70 % patient , patient suitable candidate hematopoietic stem cell transplantation ( HSCT ) due advanced age lack histocompatible donor . For patient , comparable long term survival attainable immunosuppressive treatment anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) . However , patient treat horse ATG ( h-ATG ) /CsA , one quarter one third respond , 50 % responder relapse . Auto-reactive T cell may resistant effect ATG/CsA ( non-responders ) , others residual auto-reactive T cell expand post-treatment , lead hematopoietic stem cell destruction recurrent pancytopenia ( relapse ) . As long term survival correlate response rate robustness hematopoietic recovery , novel immunosuppressive regimen achieve hematologic response decrease relapse rate need . This trial compare effectiveness three immunosuppressive regimen first line therapy patient SAA early hematologic response primary endpoint , well assess role extend CsA treatment h-ATG reduce number late event relapse clonal evolution . Randomization employ obtain equal distribution subject arm ; comparison early hematologic response make among rate observe among three concurrent arm ( rabbit-ATG [ r-ATG ] versus standard h-ATG ; alemtuzumab vs standard h-ATG ) . For long course CSA , comparison primary end point well establish historic relapse rate 38 % 2-3 year cumulative rate clonal evolution 15 % . In original design subject randomize one three different regimen : h-ATG + 6 month CsA follow 18 month CsA taper ; r-ATG + 6 month CsA ; alemtuzumab ( Campath ) . Subjects fail respond r-ATG cross alemtuzumab ( Campath ) , subject fail alemtuzumab ( Campath ) cross r-ATG . Subjects fail respond h-ATG + CsA taper go study evaluate eligibility second course immunosuppression companion protocol 03-H-0249 , similarly randomizes subject r-ATG alemtuzumab ( Campath ) salvage therapy . The Campath arm close new accrual lack efficacy 4/10/2008 . Subsequently , new accrual randomize h-ATG + 6 month CsA follow 18 month CsA taper r-ATG + 6 month CsA . Subjects fail respond h-ATG + CsA taper go study evaluate eligibility second course immunosuppression companion protocol 03-H-0249 , similarly randomizes subject r-ATG alemtuzumab ( Campath ) salvage therapy . Subjects fail respond r-ATG + 6 month CsA offer treatment h-ATG salvage therapy go off-study alternative treatment stem cell transplant ( sibling unrelated donor ) . The primary endpoint hematologic response , define longer meet criterion SAA , 6 month . Secondary endpoint relapse , robustness hematologic recovery 6 month , response 3 12 month , survival , clonal evolution PNH , myelodysplasia acute leukemia . Long-course CSA assess separately efficacy reduce late event relapse evolution comparison historical control data .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Severe aplastic anemia characterize bone marrow cellularity le 30 % ( exclude lymphocyte ) least two follow : Absolute neutrophil count le 500/microliter Platelet count le 20,000/microliter Absolute reticulocyte count less 60,000/microliter 2 . Age great equal 2 year old 3 . Weight great 12 kg EXCLUSION CRITERIA : 1 . Diagnosis Fanconi 's anemia 2 . Evidence clonal disorder cytogenetics . Patients super severe neutropenia ( ANC le 200/microliter ) exclude initially cytogenetics available pending . If evidence clonal disorder later identify , patient go study . 3 . Prior immunosuppressive therapy ATG , ALG , alemtuzumab , high dose cyclophosphamide . 4 . Infection adequately respond appropriate therapy . 5 . Serologic evidence HIV infection . 6 . Failure discontinue herbal supplement Echinacea purpurea Usnea barbata ( Old Man 's Beard ) within 2 week enrollment . 7 . Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient 's ability tolerate protocol therapy , death within 710 day likely . 8 . Potential subject cancer active chemotherapeutic treatment take drug hematological effect eligible . 9 . Current pregnancy , unwillingness take oral contraceptive refrain pregnancy childbearing potential . 10 . Not able understand investigational nature study give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 15, 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>T-cells</keyword>
	<keyword>Hematopoiesis</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>SAA</keyword>
</DOC>